Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain.

The cytochrome P4502D6 (CYP2D6) is involved in the biotransformation of many drugs which predominantly act in the central nervous system (CNS), including opioids, various psychotrophic drugs and neurotoxins. Until now, however, only controversial information is available regarding the presence of CYP2D6 in CNS. In this study, the regional and cellular expression of CYP2D6 transcripts and proteins in postmortem brain tissues of three individuals was analysed. A combination of in-situ hybridization coupled with immunohistochemistry on adjacent sections allowed simultaneous detection of CYP2D6 mRNA and protein. However, discrepancies existed in the results such that the mRNA was more widely distributed in the brain areas analysed compared to the protein. Neuronal cells, as well as glial cells, showed labelling for mRNA in brain regions such as the neocortex, caudate nucleus, putamen, globus pallidus, hippocampus, hypothalamus, thalamus, substantia nigra and cerebellum. In contrast, CYP2D6 protein was primarily localized in large principal neurons such as pyramidal cells of the cortex, pyramidal cells of the hippocampus, and Purkinje cells of the cerebellum. In glial cells, CYP2D6 protein was absent. These results provide clear evidence of CYP2D6 expression in certain regions of the CNS and may indicate the role CYP2D6 plays in a number of drug interactions that are of potential clinical importance for neurological diseases.

[1]  R. Tyndale,et al.  Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[2]  C. Hiemke,et al.  Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, Pharmacology & therapeutics.

[3]  J. Poirier,et al.  ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE , 1985, The Lancet.

[4]  M. Eichelbaum,et al.  Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. , 1996, Pharmacogenetics.

[5]  J. Plummer,et al.  Influence of polarity on dose-response relationships of intrathecal opioids in rats , 1990, Pain.

[6]  G. Baker,et al.  Metabolic Drug Interactions with Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants , 1998, Neuroscience & Biobehavioral Reviews.

[7]  S. Hsu,et al.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.

[8]  J. Clèdes,et al.  Cytochrome P450 4A and 2E1 expression in human kidney microsomes. , 1997, Biochemical pharmacology.

[9]  P. Fritz,et al.  Distribution and Cellular Localization of Prostacyclin Synthase in Human Brain , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  N. Chaudhari,et al.  An Optimized Method for In Situ Hybridization with Signal Amplification That Allows the Detection of Rare mRNAs , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[11]  S. Imaoka,et al.  Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. , 1998, Biochimica et biophysica acta.

[12]  G. Murray,et al.  Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. , 1998, Biochemical pharmacology.

[13]  D. L. Le Couteur,et al.  The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis , 1997, Journal of the Neurological Sciences.

[14]  S. Imaoka,et al.  Dopamine formation from tyramine by CYP2D6. , 1998, Biochemical and biophysical research communications.

[15]  M. Boyd,et al.  Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalytic activities. , 1993, Archives of Biochemistry and Biophysics.

[16]  P. Emson,et al.  Regional distribution of cytochrome P450 2D1 in the rat central nervous system , 1996, The Journal of comparative neurology.

[17]  G. Murray,et al.  Cytochrome P450 in normal human brain and brain tumours. , 1997, Biochemical Society transactions.

[18]  M. Eichelbaum,et al.  Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  H K Kroemer,et al.  "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.

[20]  U. Meyer,et al.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. , 1987, Biochemical and biophysical research communications.

[21]  H. Loh,et al.  Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  P. Beaune,et al.  Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. , 1998, Chemico-biological interactions.

[23]  F. Tortella,et al.  An autoradiographic study of dextromethorphan high‐affinity binding sites in rat brain: sodium‐dependency and colocalization with paroxetine , 1997, British journal of pharmacology.

[24]  D. Nelson,et al.  Genomic Cloning and Protein Expression of a Novel Rat Brain Cytochrome P-450 CYP2D18* Catalyzing Imipramine N-Demethylation* , 1996, The Journal of Biological Chemistry.

[25]  A. Juorio,et al.  Tryptamine may couple dopaminergic and serotonergic transmission in the brain. , 1990, General pharmacology.

[26]  I. Vermes,et al.  Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism , 1999, Neuroscience Letters.

[27]  R. Poulsom,et al.  Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[28]  U. Meyer,et al.  The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. , 1990, American journal of human genetics.

[29]  G. Tucker,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. , 1996, The Journal of pharmacology and experimental therapeutics.

[30]  F. Nagengast,et al.  Glutathione S-transferase, cytochrome P450, and uridine 5'-diphosphate-glucuronosyltransferase in human small intestine and liver. , 1989, Gastroenterology.

[31]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[32]  P. Seeman,et al.  Schizophrenia as a brain disease. The dopamine receptor story. , 1993, Archives of neurology.

[33]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[34]  F. Jiménez-Jiménez,et al.  Association between the oxidative polymorphism and early onset of Parkinson's disease , 1995, Clinical pharmacology and therapeutics.

[35]  C. Naranjo,et al.  Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. , 1998, Journal of clinical psychopharmacology.

[36]  R. Summers,et al.  Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. , 1990, The Journal of pharmacology and experimental therapeutics.

[37]  J. Backman,et al.  Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. , 1998, Arthritis and rheumatism.

[38]  C. Marsden,et al.  Expression and localisation of CYP2D enzymes in rat basal ganglia , 1999, Brain Research.

[39]  H. Hauri,et al.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Bouras,et al.  Cytochrome P-450 activities in human and rat brain microsomes , 2000, Brain Research.

[41]  M. Eichelbaum,et al.  Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.

[42]  W H Oldendorf,et al.  Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection , 1972, Science.

[43]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[44]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[45]  G. Gervasini,et al.  Tryptamine: a possible endogenous substrate for CYP2D6. , 1997, Pharmacogenetics.

[46]  K. Brøsen.  Differences in interactions of SSRIs , 1998, International clinical psychopharmacology.

[47]  B. Pollock,et al.  Antidepressants and drug‐metabolizing enzymes — expert group report , 1996, Acta psychiatrica Scandinavica.

[48]  J. Gustafsson,et al.  Cytochromes P450 of the 2D subfamily in rat brain. , 1995, Molecular pharmacology.